

Pierpaolo Pastina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5472347/publications.pdf>

Version: 2024-02-01

14
papers

246
citations

1163117

8
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

451
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab. <i>Oncology Letters</i> , 2020, 19, 1559-1566.	1.8	46
2	HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. <i>Cells</i> , 2020, 9, 1964.	4.1	37
3	Magnetic-Resonance-Imaging Texture Analysis Predicts Early Progression in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiation. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-8.	1.5	36
4	Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosity predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade. , 2020, 8, e000733.		32
5	Combined Epidermal Growth Factor Receptor and Beclin1 Autophagic Protein Expression Analysis Identifies Different Clinical Presentations, Responses to Chemo- and Radiotherapy, and Prognosis in Glioblastoma. <i>BioMed Research International</i> , 2015, 2015, 1-13.	1.9	18
6	CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8391.	4.1	17
7	The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma. <i>Clinical Neurology and Neurosurgery</i> , 2016, 149, 15-21.	1.4	16
8	Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 684110.	2.8	14
9	Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy. <i>BioMed Research International</i> , 2017, 2017, 1-7.	1.9	9
10	Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide. <i>World Neurosurgery</i> , 2018, 109, e662-e668.	1.3	9
11	Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. <i>Life</i> , 2021, 11, 1235.	2.4	7
12	Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?. <i>Clinical Neurology and Neurosurgery</i> , 2019, 184, 105445.	1.4	3
13	In Regard to Kubicek et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 923-924.	0.8	1
14	Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?. <i>Journal of Thoracic Oncology</i> , 2022, 17, e10-e12.	1.1	1